Ocugen

Update in progress

OCGN (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines. Its pipeline includes OCU400, a retinal gene therapy in Phase 3 for retinitis pigmentosa and Phase 1/2 for Leber congenital amaurosis; OCU410 for dry AMD; OCU410ST for Stargardt disease; OCU200 for diabetic macular edema, retinopathy, and wet AMD; and NeoCart for knee cartilage repair. It also develops OCU500 (COVID-19 vaccine), OCU510 (seasonal flu), and OCU520 (flu plus COVID-19). Collaborations with NIAID and CanSino Biologics. Founded 2013, Malvern, PA.

Company score

Sentiment: 0.82; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.61; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.26; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.24; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.53; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive